Boston Scientific Q3 Beats Expectations, Emerging Markets Boost Biz
Executive Summary
Boston Scientific reported higher than expected Q3 results, with growth across emerging markets boosting company revenue. A number of product launches across the business also helped to drive growth.
You may also be interested in...
Continued Risks Of Duodenoscopes Leads FDA To Recommend Disposable Cap Devices
After a study earlier this year found that fixed endcap duodenoscopes continued to pose a significant risk of infecting patients after being washed, the US agency is now urging providers to switch to newer-designed scopes that reduce or eliminate the risk from reprocessing, such as duodenoscopes that have interchangeable caps. The directive from the FDA is good news for Boston Scientific, which makes a disposable duodenoscope that is close to being approved by the agency.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.